{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T17:59:20Z","timestamp":1770919160173,"version":"3.50.1"},"reference-count":23,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,22]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>COVID-19 convalescent plasma (CP) may be a safe and effective treatment option in SARS-CoV-2 infection refractory to remdesivir. Infants may benefit from CP despite developing immune systems and donor variability emphasizes the need for characterization prior to use.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002507","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T15:38:46Z","timestamp":1599838726000},"page":"4278-4281","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0804-7132","authenticated-orcid":false,"given":"Zahidee","family":"Rodriguez","sequence":"first","affiliation":[{"name":"Division of Cardiology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0606-7188","authenticated-orcid":false,"given":"Andi L.","family":"Shane","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Pediatrics, Children\u2019s Healthcare of Atlanta, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Verkerke","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Center for Transfusion and Cellular Therapies, Emory University School of Medicine, Atlanta, GA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Lough","sequence":"additional","affiliation":[{"name":"LifeSouth Community Blood Centers, Inc., Gainesville, FL;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew G.","family":"Zimmerman","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Pediatrics, Children\u2019s Healthcare of Atlanta, and"},{"name":"Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA;"},{"name":"Yerkes National Primate Research Center, Atlanta, GA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehul","family":"Suthar","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Pediatrics, Children\u2019s Healthcare of Atlanta, and"},{"name":"Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA;"},{"name":"Yerkes National Primate Research Center, Atlanta, GA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Wrammert","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Pediatrics, Children\u2019s Healthcare of Atlanta, and"},{"name":"Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Department of Pathology, Children\u2019s Healthcare of Atlanta, Atlanta, GA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wolf","sequence":"additional","affiliation":[{"name":"Division of Cardiology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanelle","family":"Clarke","sequence":"additional","affiliation":[{"name":"Division of Cardiology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Roback","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Center for Transfusion and Cellular Therapies, Emory University School of Medicine, Atlanta, GA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connie M.","family":"Arthur","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Center for Transfusion and Cellular Therapies, Emory University School of Medicine, Atlanta, GA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean R.","family":"Stowell","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Center for Transfusion and Cellular Therapies, Emory University School of Medicine, Atlanta, GA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra D.","family":"Josephson","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Center for Transfusion and Cellular Therapies, Emory University School of Medicine, Atlanta, GA;"},{"name":"Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Emory University School of Medicine and Children\u2019s Healthcare of Atlanta, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2020,9,11]]},"reference":[{"issue":"6","key":"2020091111381710700_B1","doi-asserted-by":"crossref","first-page":"e20200702","DOI":"10.1542\/peds.2020-0702","article-title":"Epidemiology of COVID-19 among children in China","volume":"145","author":"Dong","year":"2020","journal-title":"Pediatrics"},{"issue":"14","key":"2020091111381710700_B2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.15585\/mmwr.mm6914e4","article-title":"Coronavirus disease 2019 in children: United States, February 12-April 2, 2020","volume":"69","author":"CDC COVID-19 Response Team","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020091111381710700_B3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jpeds.2020.05.007","article-title":"Severe COVID-19 in children and young adults in the Washington, DC metropolitan region","volume":"223","author":"DeBiasi","year":"2020","journal-title":"J Pediatr"},{"key":"2020091111381710700_B4","article-title":"Hopes rise for coronavirus drug remdesivir [published online ahead of print 29 April 2020]","author":"Ledford","journal-title":"Nature"},{"issue":"2","key":"2020091111381710700_B5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/jmv.20431","article-title":"A serological survey on neutralizing antibody titer of SARS convalescent sera","volume":"77","author":"Zhang","year":"2005","journal-title":"J Med Virol"},{"issue":"8","key":"2020091111381710700_B6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Ann Intern Med"},{"issue":"4","key":"2020091111381710700_B7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection","volume":"52","author":"Hung","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2020091111381710700_B8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1378\/chest.12-2907","article-title":"Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection","volume":"144","author":"Hung","year":"2013","journal-title":"Chest"},{"issue":"1","key":"2020091111381710700_B9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Evaluation of convalescent plasma for Ebola virus disease in Guinea","volume":"374","author":"van Griensven","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"2020091111381710700_B10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"2020091111381710700_B11","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/jac\/dki346","article-title":"Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital","volume":"56","author":"Yeh","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"16","key":"2020091111381710700_B12","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"2020091111381710700_B13","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/00000542-200303000-00009","article-title":"Risk factors for adverse postoperative outcomes in children presenting for cardiac surgery with upper respiratory tract infections","volume":"98","author":"Malviya","year":"2003","journal-title":"Anesthesiology"},{"issue":"2","key":"2020091111381710700_B14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00000542-200108000-00008","article-title":"Risk factors for perioperative adverse respiratory events in children with upper respiratory tract infections","volume":"95","author":"Tait","year":"2001","journal-title":"Anesthesiology"},{"issue":"1","key":"2020091111381710700_B15","doi-asserted-by":"crossref","first-page":"e20170009","DOI":"10.1542\/peds.2017-0009","article-title":"Upper respiratory infections and airway adverse events in pediatric procedural sedation","volume":"140","author":"Mallory","year":"2017","journal-title":"Pediatrics"},{"issue":"1","key":"2020091111381710700_B16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1460-9592.2001.00607.x","article-title":"Clinical predictors of anaesthetic complications in children with respiratory tract infections","volume":"11","author":"Parnis","year":"2001","journal-title":"Paediatr Anaesth"},{"key":"2020091111381710700_B17","doi-asserted-by":"crossref","first-page":"m1256","DOI":"10.1136\/bmj.m1256","article-title":"Covid-19: FDA approves use of convalescent plasma to treat critically ill patients","volume":"368","author":"Tanne","year":"2020","journal-title":"BMJ"},{"issue":"5","key":"2020091111381710700_B18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(20)30196-1","article-title":"Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study","volume":"20","author":"To","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"2020091111381710700_B19","first-page":"100040","article-title":"Rapid generation of neutralizing antibody responses in COVID-19 patients","volume":"1","author":"Suthar","year":"2020","journal-title":"medRxiv"},{"key":"2020091111381710700_B20","unstructured":"FDA. Recommendations for investigational COVID-19 convalescent plasma. https:\/\/www.fda.gov\/vaccines-blood-biologics\/investigational-new-drug-ind-or-device-exemption-ide-process-cber\/recommendations-investigational-covid-19-convalescent-plasma. Accessed 1 May 2020."},{"issue":"6","key":"2020091111381710700_B21","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1172\/JCI138745","article-title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19","volume":"130","author":"Bloch","year":"2020","journal-title":"J Clin Invest"},{"issue":"22","key":"2020091111381710700_B22","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1001\/jama.2020.8259","article-title":"Interpreting diagnostic tests for SARS-CoV-2","volume":"323","author":"Sethuraman","year":"2020","journal-title":"JAMA"},{"key":"2020091111381710700_B23","article-title":"Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region [published online ahead of print 5 May 2020]","author":"Wajnberg","journal-title":"medRxiv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/18\/4278\/1757955\/advancesadv2020002507.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/18\/4278\/1757955\/advancesadv2020002507.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T15:38:59Z","timestamp":1599838739000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/18\/4278\/463720\/COVID19-convalescent-plasma-clears-SARSCoV2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":23,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2020,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002507","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,11]]}}}